| Flavius Martin |
Flavius Martin currently works at Gilead Sciences, Inc., as Executive Vice President-Research from 2021. Dr. Martin also formerly worked at Amgen, Inc., as Vice President-Research Biology. Dr. Martin received his doctorate degree from Universitatea de Medicina si Farmacie Victor Babes. |
| Diane E. Wilfong |
Diane E. Wilfong currently works at IPI Legacy Liquidation Co., as Independent Director from 2019, The American Institute of Certified Public Accountants, as Member, and Gilead Sciences, Inc., as Chief Accounting Officer & Controller from 2025. Ms. Wilfong also formerly worked at CSRA, Inc., as Director, Computer Sciences Corp., as Chief Accounting Officer & Controller from 2014 to 2016, Eastman Kodak Co., as Chief Accounting Officer & Controller from 1999 to 2009, Gilead Sciences, Inc., as Chief Accounting Officer, VP & Controller from 2016 to 2020, Caesars License Co. LLC, as Chief Accounting Officer, Senior VP & Controller in 2012, PricewaterhouseCoopers LLP, as Audit Manager in 1990, Corning Asahi Video Products Co., as Chief Financial Officer, and Caesars Holdings, Inc., as Chief Accounting Officer, Senior VP & Controller from 2009 to 2014. Ms. Wilfong received her undergraduate degree from Kenan-Flagler Business School. |
| Daniel P. O'Day |
Daniel P. O'Day currently works at Gilead Sciences, Inc., as Chairman & Chief Executive Officer from 2019, Pharmaceutical Research & Manufacturers of America, as Chairman from 2024, Pharmaceutical Manufacturers Association of America, as Director, and Shanghai Roche Pharmaceuticals Ltd., as Director. Mr. O'Day also formerly worked at Roche Pharmaceuticals, Inc., as Chief Executive Officer from 2012 to 2018, Roche Molecular Systems, Inc., as President & Chief Executive Officer, Genentech, Inc., as Director, Chugai Pharmaceutical Co., Ltd., as Director, Roche Diagnostics GmbH, as Director from 2010 to 2012, Foundation Medicine, Inc., as Director, Flatiron Health, Inc., as Director, Galapagos NV, as Non-Independent Non-Executive Director from 2023 to 2024, Roche Holding AG, as COO-Roche Pharmaceuticals Division, Roche Diagnostics KK, as Head-Corporate Planning, Roche Diagnostics A, as Chief Operating Officer from 1999 to 2012, Roche Pharma (Schweiz) AG, as Head-Business Unit, Arthritis & Respiratory from 1998 to 1999, and Roche A, as General Manager in 2006. Mr. O'Day received his Masters Business Admin degree in 1997 from The Trustees of Columbia University in The City of New York and undergraduate degree in 1986 from Georgetown University. |
| Dietmar P. Berger |
Dietmar P. Berger currently works at Arcus Biosciences, Inc., as Director from 2025, the University of Freiburg, as Professor-Medicine, Sanofi AATD, Inc., as President from 2024, and Gilead Sciences, Inc., as Chief Medical Officer from 2025. Dr. Berger also formerly worked at Genentech, Inc., as Vice President-Clinical Hematology & Oncology from 2011 to 2018, The Scripps Research Institute, as Head-Clinical Research Centre, Universitätsklinikum Freiburg, as Head-Clinical Research Centre, Atara Biotherapeutics, Inc., as Global Head-Research & Development from 2018 to 2019, and Sanofi, as Chief Medical Officer & Global Head-Development. Dr. Berger received his graduate degree and doctorate degree from the University of Freiburg. |
| Christi L. Shaw |
Christi L. Shaw is the founder of More Moments More Memories Foundation. Current jobs include Executive Director at Biotechnology Innovation Organization since 2014, Independent Director at Beam Therapeutics, Inc. since 2023, Independent Director at Kyverna Therapeutics, Inc. since 2024, and Director at ReAlta Life Sciences, Inc. since 2024. Former jobs include Chief Executive Officer at Kite Pharma, Inc. from 2019 to 2023, Group Product Director at Janssen Pharmaceuticals, Inc. in 2004, Director at Healthcare Leadership Council, Director at The Young Women's Leadership Network, Inc., Independent Director at Avantor, Inc. from 2018 to 2024, Principal at Johnson & Johnson, President-Bio Medicines & Senior Vice President at Eli Lilly & Co. from 2017 to 2019, Head-North American Region at Novartis Oncology, Inc., President & Country Head-US at Novartis Pharmaceuticals Corp. from 2014 to 2016, VP-New Business Development & Strategic Analytics at Ethicon Corp., and Advisor at Concord Health Partners LLC. Education includes an undergraduate degree from Iowa State University and an MBA from the University of Wisconsin. |
| Johanna Mercier |
Ms. Johanna Mercier is an Independent Director at Neurocrine Biosciences, Inc., a Chief Commercial Officer at Gilead Sciences, Inc. and a Member at World 50, Inc. She is on the Board of Directors at Arcus Biosciences, Inc., Neurocrine Biosciences, Inc., Leonard D Schaeffer Center For Health Policy & Economics and Robert Wood Johnson University Hospital, Inc. Ms. Mercier was previously employed as a President-US Commercial by Bristol Myers Squibb Co. She received her undergraduate degree from the University of Montréal and an MBA from Concordia University. |
| Andrew D. Dickinson |
Andrew D. Dickinson currently works at Immunomedics, Inc., as President, Treasurer & Director from 2020, Sutter Health, as Director from 2021, Forty Seven LLC, as President, Treasurer & Director from 2020, Fosun Kite Biotechnology Co., Ltd., as Director, Gilead Sciences Ltd., as Director from 2019, Galapagos NV, as Non-Independent Non-Executive Director from 2024, Gilead Sciences, Inc., as Chief Financial Officer from 2019, and CymaBay Therapeutics, Inc., as Chief Executive & Financial Officer. Mr. Dickinson also formerly worked at Gilead Colorado, Inc., as Secretary, Vice President & General Counsel from 2004 to 2006, Lazard, Inc., as Co-Head-Healthcare Investment Banking, and Kendall Dickinson & Koenig LLC, as Founding Partner. Mr. Dickinson received his graduate degree in 1996 from Loyola University of Chicago and undergraduate degree in 1993 from The University of Colorado. |
| Anthony Welters |
Anthony Welters was the founder of AmeriChoice Corp. (1989), serving as President & Chief Executive Officer; Somatus, Inc. (2016), serving as Chairman; and Cinqcare (2021), serving as Chairman & Chief Executive Officer. Current jobs include Vice Chairman at New York University, Vice Chairman at The John F. Kennedy Center for the Performing Arts, Chairman at Morehouse School of Medicine, Chairman at New York University School of Law, Executive Chairman at BlackIvy Group LLC (2014), Lead Independent Director at Gilead Sciences, Inc. (2020), Director at Carlyle Investment Management LLC (2015), Director at The Horatio Alger Association of Distinguished Americans, Independent Director at The Carlyle Group Inc. (2015), Director at Horatio Alger Association of US, Director at Parachute Health, LLC, Member at Smithsonian National Museum of American History, Trustee at The Library of Congress (District of Columbia), Member at American Academy of Arts & Sciences, Member at The District of Columbia Bar, Member at The New York Bar Foundation, Trustee at NYU Langone Hospitals, Member at The National Museum of African American History & Culture, Trustee at NYU Langone Health, Trustee at New York University School of Medicine, and Board Member at The Carlyle Group LP (Global Private Equity). Former jobs include Independent Director at C. R. Bard, Inc. (2011-2017), Director at Qwest Communications International, Inc. (2006-2011), Independent Director at West Pharmaceutical Services, Inc. (1997-2016), Independent Director at Carlyle Group Management LLC, Independent Director at Loews Corp. (2013-2025), and Executive Vice President at UnitedHealth Group, Inc. (2011-2014). Education includes an undergraduate degree from Manhattanville College and a graduate degree from New York University School of Law. |
| Jeffrey A. Bluestone |
Jeffrey A. Bluestone was the founder of Celsius Therapeutics, Inc. (2018), Xconomy, Inc. (2007), Immune Tolerance Network (1999), and Sonoma Biotherapeutics, Inc. (2019) holding the titles of Chief Executive Officer at Xconomy, Inc., Director at Immune Tolerance Network, and President, Chief Executive Officer & Director at Sonoma Biotherapeutics, Inc. Current jobs include Vice Chairman at The Parker Institute For Cancer Immunotherapy (2020), Independent Director at Gilead Sciences, Inc. (2020), Member at National Academy of Sciences, Professor at The University of California, San Francisco, Member at American Academy of Arts & Sciences, and Member at National Academy of Medicine (United States). Former jobs include Independent Director at Provention Bio, Inc. (2019-2022), Director at Rheos Medicines, Inc., and Director & Professor at The Ben May Department For Cancer Research. Education includes a graduate degree from Rutgers State University of New Jersey and a doctorate from Weill Cornell Graduate School of Medical Sciences. |
| Kelly A. Kramer |
Kelly A. Kramer currently works at Gilead Sciences, Inc., as Independent Director from 2016, Coinbase, Inc., as Director from 2020, City Year San Jose, as Director, Snowflake, Inc., as Independent Director from 2020, Coinbase Global, Inc., as Independent Director from 2020, and Consello Capital LLC, as Senior Advisor. Ms. Kramer also formerly worked at Figma, Inc., as Director, Cisco Systems, Inc., as Chief Financial Officer & Executive Vice President from 2015 to 2020, Global Life Sciences Solutions USA LLC, as Chief Financial Officer from 2006 to 2007, and GE Healthcare, Inc., as CFO-Healthcare Systems Business & Vice President from 2001 to 2002. Ms. Kramer received her undergraduate degree in 1989 from Purdue University. |
| Jacqueline K. Barton |
Jacqueline K. Barton was the founder of GeneOhm Sciences, Inc. and served as Director from 2001 to 2005. Current jobs include Independent Director at Gilead Sciences, Inc. since 2018, Member at The Royal Society of Chemistry since 2014, Professor at California Institute of Technology since 1989, Member at National Academy of Sciences since 2002, Member at American Academy of Arts & Sciences since 1991, Member at National Academy of Medicine (United States) since 2012, and Vice President & Member at American Philosophical Society since 2021. Former jobs include Director at The Dow Chemical Co. from 1993 to 2017, Director at Dow Wolff Cellulosics GmbH & Co. KG, Director at DuPont de Nemours, Inc. from 2018 to 2019, Independent Director at Dow, Inc. from 1993 to 2021, Professor at The Trustees of Columbia University in The City of New York from 1983 to 1989, and Assistant Professor at Hunter College in 1982. Education includes a doctorate from The Trustees of Columbia University in The City of New York and an undergraduate degree from Barnard College, conferred in 1974. |
| Sandra J. Horning |
Sandra J. Horning was the founder of EQRx International, Inc. (2020) and EQRx, Inc. (2019) with the title of Independent Director from 2019 to 2023. Current jobs include Independent Director at Gilead Sciences, Inc. (2020), Independent Director at Revolution Medicines, Inc. (2023), Independent Director at Olema Pharmaceuticals, Inc. (2020), Independent Director at Moderna, Inc. (2020), Director at Cellarity Inc. (2022), and Professor at Stanford University School of Medicine (1998-2009). Former jobs include Director at Foundation Medicine, Inc. (2015-2018), Chief Medical Officer & EVP-Global Development at Genentech, Inc. (2014-2019), Chief Medical Officer at Roche Holdings, Inc. (2009-2019), President at American Society of Clinical Oncology, Inc. (2005-2006), and Chief Medical Officer & Head-Product Development at Roche, Inc. (2013-2019). Education includes undergraduate and doctorate degrees from the University of Iowa. |
| Ted W. Love |
Ted W. Love currently works at Biotechnology Innovation Organization, as Chairman, Gilead Sciences, Inc., as Independent Director from 2024, Avillion LLP, as Non-Executive Director from 2014, Structure Therapeutics, Inc., as Independent Director from 2023, Royalty Pharma Plc, as Independent Director from 2020, and Life Science Cares Bay Area, as Director. Dr. Love also formerly worked at Nuvelo, Inc., as Chairman, President & Chief Executive Officer in 2009, Global Blood Therapeutics, Inc., as President, Chief Executive Officer & Director from 2014 to 2022, Bio-Rad Laboratories, Inc., as Independent Director from 2011 to 2013, Seagen, Inc., as Independent Director from 2020 to 2023, Mast Therapeutics, Inc., as Independent Director from 2012 to 2013, Anesiva, Inc., as Director, Santarus, Inc., as Independent Director from 2011 to 2014, Amicus Therapeutics, Inc., as Independent Director from 2012 to 2020, Humanigen, Inc., as Lead Independent Director in 2015, Predix Pharmaceuticals, Inc., as Director, Portola Pharmaceuticals LLC, as Independent Director from 2019 to 2020, ARCA biopharma, Inc., as Director in 2009, Cascadian Therapeutics LLC, as Independent Director from 2014 to 2018, Affymax, Inc., as Independent Director from 2011 to 2013, Stanford Health Care, as Director, California Healthcare Institute, as Director, California Institute for Regenerative Medicine, as Director from 2004 to 2006, The Biotechnology Institute, as Director, ARCA biopharma, Inc., as Director in 2011, Genentech, Inc., as VP-Product Development & Regulatory Affairs from 1992 to 1998, Onyx Pharmaceuticals, Inc., as Executive VP & Head-Research & Development from 2011 to 2012, Innoviva, Inc., as Senior Vice President-Development from 1998 to 2001, and Theravance Biopharma US, Inc., as Senior Vice President-Development from 1998 to 2001. Dr. Love received his undergraduate degree from Haverford College and doctorate degree from Yale School of Medicine. |
| Javier J. Rodriguez |
Javier J. Rodriguez was the founder of DomoBlue SL, serving as Chairman from 2009 to 2012. Current jobs include Chief Executive Officer & Director at DaVita, Inc. since 2019, Chief Executive Officer at PwC Product Sales LLC, Independent Director at Gilead Sciences, Inc. since 2020, Director at Denver Metro Chamber of Commerce, and Senior Vice President at Renal Care Centers Corp. since 1998. Former jobs include President & Chief Executive Officer at DaVita Kidney Care Contracting LLC from 2014 to 2019, Operations Director at CBS Marketing, Inc., and Principal at Baxter Healthcare Corp. in 1996. Education includes an undergraduate degree from Boston College and an MBA from Harvard Business School. |
| Harish M. Manwani |
Harish M. Manwani currently works at Indian School of Business, as Chairman-Executive Board, Gilead Sciences, Inc., as Independent Director from 2018, Whirlpool Corp., as Independent Director from 2011, The Nielsen Company (US) LLC, as Director, Tata Sons Pvt Ltd., as Director, EDB Investments Pte Ltd, as Director, Blackstone, Inc., as Senior Managing Director-Portfolio Operations, and EDBI Pte Ltd., as Director. Mr. Manwani also formerly worked at Unilever HPC Co., as President & Chief Executive Officer from 2004 to 2005, Hindustan Unilever Ltd., as Non-Executive Chairman from 2005 to 2018, Alinamin Pharmaceutical Co., Ltd., as Chairman, QUALCOMM, Inc., as Independent Director from 2014 to 2022, ING Groep NV, as Director in 2010, Pearson Plc, as Independent Non-Executive Director from 2013 to 2018, Nielsen NV, as Independent Non-Executive Director, Nielsen Holdings Ltd., as Independent Non-Executive Director from 2015 to 2021, Singapore Economic Development Board, as Director, Nielsen NV (Old), as Director, Human Capital Leadership Institute, as Director from 2012 to 2014, Unilever Plc, as Chief Operating Officer from 2011 to 2014, and Economic Development Board of Singapore, as Member from 2013 to 2019. Mr. Manwani received his undergraduate degree and graduate degree from the University of Mumbai and graduate degree from Harvard Business School. |
